Since late 2023, improved liquidity and valuation repairs have fueled a structural bull market in Hong Kong stocks, with secondary new stocks (listed within two years) emerging as a key source of alpha. Seventeen such stocks have doubled year-to-date, led by consumer plays like bubble tea chain Mixue Group (+85%) and jeweler Laopu Gold (+277%), alongside biotech firms benefiting from global R&D tailwinds. The rally reflects capital chasing high-growth niches—from discretionary spending to gold’s safe-haven appeal—amid China’s consumption recovery.
The surge stems from southbound inflows ($12B YTD), policy support (HKEX reforms), and attractive entry valuations (30% discount to A-shares pre-rally). However, stretched multiples—Laopu Gold trades at 50x P/E—raise sustainability concerns. The upcoming interim earnings season (July-August) will test whether growth justifies premiums, with stocks needing >30% profit gains to sustain momentum.
Funds are pivoting to late-stage biotech IPOs and undervalued consumer brands, betting on catalysts like ASCO data and holiday demand. While the secondary new stock boom underscores Hong Kong’s role as a liquidity-driven market, selectivity is now key as dispersion widens between winners and overhyped names.
related topics：
